Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry.
Endocytosis
HBV
Vimentin
hzVSF
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
12
01
2021
revised:
10
04
2021
accepted:
12
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
Although nucleos(t)ide analogs and interferons suppress hepatitis B virus (HBV) replication, they must be taken continuously and have a low response rate. Therefore, therapeutics for HBV with novel modes of action are needed. Humanized virus-suppressing factor (hzVSF) is a monoclonal antibody against vimentin that exhibits broad-spectrum antiviral activity. Here, hzVSF significantly inhibited HBV infection. Although hzVSF inhibited HBV RNA production, it did not affect viral transcription from minicircle DNA mimicking covalently closed circular DNA. Additionally, hzVSF did not inhibit viral protein or DNA release from infected cells. Rather, hzVSF inhibited the cell entry of viral preS1 peptides, possibly by altering intracellular vimentin localization, which is important for HBV cell entry. These results suggest that hzVSF has therapeutic potential for HBV infection with a novel mode of action.
Identifiants
pubmed: 34345745
doi: 10.1016/j.heliyon.2021.e07586
pii: S2405-8440(21)01689-3
pmc: PMC8319007
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e07586Informations de copyright
© 2021 The Author(s).
Références
Sci Rep. 2016 Nov 07;6:36483
pubmed: 27819342
Ann Transl Med. 2016 Sep;4(18):337
pubmed: 27761441
J Hepatol. 2016 Oct;65(4):683-691
pubmed: 27210429
Gastroenterology. 2019 Jan;156(2):311-324
pubmed: 30243618
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Clin Liver Dis. 2019 Aug;23(3):535-555
pubmed: 31266626
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8487-8492
pubmed: 30952782
Cells. 2020 Jun 18;9(6):
pubmed: 32570893
Antiviral Res. 2016 Sep;133:156-64
pubmed: 27515132
J Hepatol. 2017 Jun;66(6):1149-1157
pubmed: 28213165
Hepatology. 2021 Jan;73(1):41-52
pubmed: 32189364
Front Microbiol. 2018 Jul 18;9:1611
pubmed: 30072974
World J Gastroenterol. 2005 Apr 7;11(13):1995-9
pubmed: 15800993
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4574-E4581
pubmed: 28533359
J Biol Chem. 2020 Jan 17;295(3):800-807
pubmed: 31836663
Cell Mol Gastroenterol Hepatol. 2019;7(2):297-312
pubmed: 30704981
Infect Immun. 2012 Nov;80(11):3795-803
pubmed: 22890997
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20
pubmed: 9257747
J Hepatol. 2017 Apr;66(4):685-692
pubmed: 27890789
Hepatology. 2013 Jan;57(1):162-70
pubmed: 22898998
Gastroenterology. 2019 Jan;156(2):297-310
pubmed: 30391470
J Med Virol. 2020 Nov;92(11):2371-2373
pubmed: 32458425
Lancet Gastroenterol Hepatol. 2019 Nov;4(11):883-892
pubmed: 31609242
Hepatology. 2019 May;69(5):1903-1915
pubmed: 30586159
J Virol. 2013 Jul;87(14):7977-91
pubmed: 23678176